FURX Description — Furiex Pharmaceuticals Inc
Furiex Pharmaceuticals is a drug development collaboration company. Co.'s collaborations mainly involve late-stage development and commercialization agreements with other pharmaceutical companies. As of Dec 31 2012, Co. had rights to several compounds in various stages of development and commercialization including: alogliptin and SYR-472, for the treatment of Type-2 diabetes; Priligy®, a treatment for premature ejaculation; Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections.